Bristol Myers' Lead Cancer Drug Opdivo Regime Meets Primary Goal In Phase 3 Lung Cancer Study
Portfolio Pulse from Vandana Singh
Bristol Myers Squibb & Co (NYSE:BMY) announced that its lead cancer drug, Opdivo, met its primary goal in a Phase 3 lung cancer study. The trial showed a significant improvement in event-free survival (EFS) compared to neoadjuvant chemotherapy and placebo. The company plans to share the results at an upcoming medical conference and discuss with health authorities.
September 22, 2023 | 2:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers' Opdivo met its primary goal in a Phase 3 lung cancer study, potentially boosting the company's reputation and stock value.
Positive clinical trial results often lead to increased investor confidence, potentially driving up the stock price. The success of Opdivo, a lead drug, is particularly significant for Bristol Myers.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100